UPCOMING SESSIONS in ET
Thu, Jun 25, 2026
5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN Richard Wlodarski Click To Register
UPCOMING SESSIONS in ET
Thu, Jun 25, 2026 · 5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN
Richard Wlodarski
Click To Register
View all sessions

Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis

Source
Oxford Academic

Abstract

Background

Cardiac amyloidosis (CA) is an under-recognized cause of heart failure. Its prevalence in screening studies, and the extent to which selective confirmatory testing affects prevalence estimates, remain uncertain across clinical settings.

Methods

We systematically searched PubMed/MEDLINE and EMBASE up to 10 August 2025. Two reviewers independently screened studies and extracted data. We grouped studies by clinical setting and combined prevalence estimates using random-effects meta-analysis. For each study, we calculated CA prevalence in 1) the whole enrolled cohort and 2) the subgroup who underwent confirmatory testing.